Seminars in Hematology
Volume 37, Issue 1 , Pages 43-55 , January 2000

Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia

  • David A Margolis

      Affiliations

    • Corresponding Author InformationAddress reprint requests to David A. Margolis, MD, Medical College ofWisconsin, 8701 Watertoum Plank Rd, Milwaukee, WI 53226.
    • ,
  • James T Casper

References 

  1. Anasetti C, Amos D, Beatty PG, et al.  Effect of HIA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197–204
  2. Anasseti C, Beatty PG, Storb R, et al.  Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29:79–91
  3. Ash R, Casper J, Chitambar C, et al.  Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA matched unrelated donors. N Engl J Med. 1990;322:485–494
  4. Bacigalupo A, Broccia G, Corda G, et al.  Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party. Blood. 1995;85:1348–1353
  5. Baur MP, Neugebauer M, Albert ED. Reference tables of two-locus haplotype frequencies for all MHC marker loci. In:  Albert ED,  Baur MP,  Mayr WR editor. Histocompatibility Testing 1984. Berlin, Germany: Springer-Verlag; 1984;p. 677–682
  6. Baxter-Lowe LA, Casper JT. HLA testing. In:  Gross S,  Roath S editor. Hematology: A Problem-Oriented Approach. Baltimore, MD: Williams and Wilkins; 1996;p. 691–699
  7. Baxter-Lowe LA, Parrish R, Margolis D, et al.  HLA disparity detected by automated nucleotide sequencing may aid in selection of alternative donors. Blood. 1997;90(suppl 1):109a; abstr
  8. Beatty PG, Clift RA, Mickelson EM, et al.  Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–771
  9. Beatty PG, Thomas ED, Hansen JA. The Seattle experience with partially matched related donors and matched unrelated donors. In:  Fauci AS,  Lenfant C,  Devita VT, et al. editor. Donor Registries for Bone Marrow Transplantation. NIH Technology Access Statement Online (2). May 13–15, 1985;p. 16
  10. Beatty PG, Dahlberg S, Mickelson EM, et al.  Probability of finding HLA-matched unrelated marrow donors. Transplantation. 1988;45:714–718
  11. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation. 1995;60:778–783
  12. Beatty PG, Di Bartolomeo P, Storb R, et al.  Treatment of aplastic anemia with marrow grafts from related donors other than HLA genotypically matched siblings. Clin Transplant. 1987;1:117–124
  13. Bodmer JG, Marsh SGE, Albert ED, et al.  Nomenclature for factors of the HLA system, 1996. Tissue Antigens. 1997;49:297–321
  14. Bonini C, Ferrari G, Verzeletti S, et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719–1724
  15. Camitta B, Ash R, Menitove J, et al.  Bone marrow transplantation for children with severe aplastic anemia: Use of donors other than HLA-identical siblings. Blood. 1989;74:1852–1857
  16. Camitta B, Deeg HJ, Castro-Malaspina H, et al.  Unrelated or mis-matched bone marrow transplants for aplastic anemia: Experience at four major centers. In:  Gluckman E,  Coulombel L editor. Ontogeny of Hematopoiesis. Aplastic Anemia. Montrouge, France: Libbey; 1995;p. 325–330
  17. Casper J, Camitta B, Truitt R, et al.  Unrelated bone marrow transplants for children with leukemia or myelodysplasia. Blood. 1995;85:2354–2363
  18. Champlin RE, Horowitz MM, van Bekkum DW, et al.  Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results. Blood. 1989;73:606–613
  19. Confer D. In: Changes and challenges for the NMDP Presented at the NMDP 1999 Transplant Center Spring Meeting. Park City, UT. April 12–13, 1999;
  20. Cuthbert RJ, Shepherd JD, Nantel SH, et al.  Allogeneic bone marrow transplantation for severe aplastic anemia: The Vancouver experience. Clin Invest Med. 1995;18:122–130
  21. Davies SM, Shu XO, Blazar BR, et al.  Unrelated donor bone marrow transplantation: Influence of HLA-A and -B incompatibility on outcome. Blood. 1995;86:1636–1642
  22. Deeg HJ, Anasetti C, Petersdorf E, et al.  Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. Blood. 1994;83:3417–3418 (letter)
  23. Deeg HJ, Amylon M, Collins R, et al.  Marrow transplantation from unrelated donors (UDT) in patients with aplastic anemia (AA) who have failed immunosuppressive therapy. Exp Hematol. 1996;24:1143; (abstr)
  24. Deeg HJ, Seidel K, Casper J, et al.  Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5:243–252
  25. Deeg HJ, Schoch G, Ramsey N, et al.  Marrow transplantation from unrelated donors for patients with aplastic anemia (AA) who failed immunosuppressive therapy. Blood. 1997;90:1765; (abstr 1763)
  26. Duell T, van Lint MT, Ljungman P, et al.  Health and functional status of long-term survivors of bone marrow transplantation. Ann Intern Med. 1997;126:184–192
  27. Filipovich AH, Youle RJ, Neville DM, et al.  Ex vivo treatment of donor bone marrow with and T-cell immunotoxins for prevention of graft-versus-host disease. Lancet. 1984;1:469–472
  28. Gajewski J, Gjerston D, Cecka M, et al.  The impact of T-cell depletion on the effects of HLA DRBI and DQ6 allele matching in HLA serological identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997;3:76–82
  29. Gajewski JL, Chattopadhyay A. Treatment of aplastic anemia with bone marrow transplants from closely matched unrelated donors. In:  Champlin RE,  Gale RP editor. New Strategies in Bone Marrow Transplantation. New York, NY: Wiley-Liss; 1991;p. 101–110
  30. Guinan EC, Vassilikia A, Boussiotis VA, et al.  Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340:1704–1714
  31. Hale G, Waldmann H. Recent results using Campath-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant. 1996;17:305–308
  32. Hansen JA, Petersdorf EW. Unrelated donor hematopoietic cell transplantation. In:  Thomas ED,  Blume KG,  Forman SJ editor. Hematopoietic Cell Transplantation. ed 2. Malden, MA: Blackwell Science; 1999;p. 915–928
  33. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al.  Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89:3864–3872
  34. Henslee-Downey PJ, Parrish RS, Macdonald JS, et al.  Combined ex vivo and in vivo T-lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation. 1996;61:738–745
  35. Hows J, Stone JV, Camitta B. Alternative donor bone marrow transplantation for severe acquired aplastic anemia, in Schrezemeier H (ed): Aplastic Anemia. Cambridge, UK, Cambridge University Press (in press)
  36. Hows JM, Szydlo R, Anasetti C, et al.  Unrelated donor marrow transplants for severe acquired aplastic anemia. Bone Marrow Transplant. 1992;10:102–106
  37. Hows JM, Yin JL, Marsh J, et al.  Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood. 1986;68:1322–1328
  38. Kolb HJ, Schattenberg A, Goldman JM, et al.  Graft-versus-leukemia effect on donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  39. Keever CA, Leong N, Cunningham I, et al.  HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation. Bone Marrow Transplant. 1994;14:137–145
  40. Kernan NA, Bartsch G, Ash RC, et al.  Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program. N Engl J Med. 1993;328:593–602
  41. Kernan NA. T-cell depletion for the prevention of graft-versus-host disease. In:  Thomas ED,  Blume KG,  Forman SJ editor. Hematopoietic Cell Transplantation. ed 2. Maiden, MA: Blackwell Science; 1999;p. 186–196
  42. Kurtzberg J, Laughlin M, Graham ML, et al.  Placental blood as a source of hematopoietic stem cells for transplantation into related recipients. N Engl J Med. 1996;335:157–166
  43. Leiper AD. What is in store after stem-cell transplantation?. Lancet. 1999;353:1544–1545
  44. Locatelli F, Porta F, Zecca M, et al.  Successful bone marrow transplantation in children with severe aplastic anemia using HLA-partially matched family donors. Am J Hematol. 1993;42:328–333
  45. Locasciulli A, van't Heer L, Hows J, et al.  Bone marrow transplantation (BMT) in children with severe aplastic anemia (SAA) from donors other than HLA identical siblings. EBMT Working Party on Severe Aplastic Anemia. Bone Marrow Transplant. 1991;7(suppl 3):90–91
  46. Margolis D, Camitta B, Pietryga D, et al.  Unrelated donor bone marrow transplantation to treat severe aplastic anemia in children and young adults. Br J Haematol. 1996;94:65–72
  47. Margolis DA, Casper JT. Allogeneic transplantation for Acute Myeloid Leukemia in children. In:  Thomas ED,  Blume KG,  Forman SJ editor. Hematopoietic Cell Transplantation. Maiden, MA: Blackwell Science; 1999;p. 835–848
  48. Marsh SGE, Bodmer JG. HLA class II nucleotide sequences. Hum Imunnol. 1992;35:1–17
  49. Marsh JC, Gordon-Smith EC. Treatment options in severe aplastic anemia. Lancet. 1998;351:1830–1831
  50. Martin PJ, Hansen JA, Buckner CD, et al.  Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985;66:664–672
  51. matloub YH, Bostrom B, Golembe B, et al.  Antithymocyte globulin, cyclosporin, and prednisone for the treatment of severe aplastic anemia in children. Am J Pediatr Hematol Oncol. 1994;16:104–106
  52. Mickelson EM, Fefer A, Thomas DE. Aplastic anemia: failure of patient leukocytes to stimulate allogeneic cells in mixed leukocyte culture. Blood. 1976;47:793–799
  53. Mitsuyasu PT, Champan RE, Gale PP, et al.  Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus host disease: A prospective, randomized, double-blind study. Ann Intern med. 1986;105:20–26
  54. Nash RA, Antin J, Karanes C, et al.  Phase III study comparing tacrolimus (RK506) with cyclosporine (CSP) for prophylaxis of acute graft-versus-host disease (GVHD) after marrow transplantation from unrelated donors. Blood. 1997;90(suppl 1):561a; abstr
  55. Niederwieser D, Pepe M, Storb R, et al.  Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anemia. Br J Haematol. 1988;69:23–28
  56. Passweg JR, Socie G, Hinterberger W, et al.  Bone marrow transplant for severe aplastic anemia: Has outcome improved?. Blood. 1997;90:858–864
  57. Patterson J, Prentice HG, Brenner MK, et al.  Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol. 1986;63:221–230
  58. Petersdorf EW, Longton GM, Anasetti C, et al.  Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood. 1997;89:1818–1823
  59. Petersdorf EW, Longton GM, Anasetti C, et al.  The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood. 1995;86:1606–1613
  60. Prasad VK, Kernan NA, Heller G, et al.  HLA-C disparity between patients and unrelated donor matched for HLA-A, -B, and -DRB1 alleles: Impact of serological vs. DNA typing for HLA-A and -B loci. Biol Blood Marrow Transplant. 1999;5:77–85
  61. Reisner Y, Kapoor N, Kirkpatrick D, et al.  Transplantation for severe combined immunodeficiency with HLA-A, B, D, DP, incompatibility parent marrow graft fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61:341–348
  62. Rosenthal SJ, Young NS. Aplastic anemia treated by immunosuppression is a chronic relapsing illness, but prognosis is unaffected by relapse. Blood. 1997;90(suppl 1):435a; abstr 1929
  63. Rubinstein P, Carrier C, Scaradavou A, et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565–1576
  64. Sasazuki T, Juji T, Morishima Y, et al.  Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998;339:1177–1185
  65. Schmitz N, Dreger P, Suttorp M, et al.  Primary transplantation of allogeneic peripheral blood progenitors mobilized by G-CSF (granulocyte-colony-stimulating factor). Blood. 1995;85:1666–1672
  66. Storb R, Etzioni R, Anasetti C, et al.  Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941–949
  67. Storb R, Leisenring W, Anasetti C, et al.  Long-term follow-up of allogeneic marrow transplant in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood. 1997;89:3890–3891 (letter)
  68. Storb R, Prentice RL, Buckner CD, et al.  Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983;308:302–307
  69. Storb R, Deeg HJ, Farewell V, et al.  Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine widi prevention of acute graft-versus-host disease. Blood. 1986;68:119–125
  70. Storb R, Leisenring W, Deeg HJ. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood. 1999;83:2749–2750 (letter)
  71. Takahashi K, Juji T, Miyazaki H. Determination of an appropriate size of unrelated donor pool to be registered for HLA-matched bone marrow transplantation. Transfusion. 1989;29:311–316
  72. Truitt RL, Ash RC. Manipulation of T-cell content in transplanted human bone marrow: Effect on GVH and GVL reactions. In:  Truitt RL,  Gale RP,  Bortin MM editor. Cellular Immunotherapy of Cancer. New York, NY: Liss; 1987;p. 409–421
  73. Wagner JL, Deeg HJ, Seidel K, et al.  Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives: An update of the Seattle experience. Transplantation. 1996;61:54–61
  74. Wagner JE, King R, Kollman C, et al.  Unrelated donor bone marrow transplantation (BMT) in 5075 patients with malignant and non-malignant disorders: Impact of marrow T cell depletion (TCD). Blood. 1998;92(suppl 1):686a; abstr 2826
  75. Wagner JE, Dornenberg AD, Noga SJ, et al.  Lymphocyte depletion of donor bone marrow by counter flow centrifugal elutriation: Results of a phase I clinical trial. Blood. 1988;72:1168–1176
  76. Wagner JL, Storb R. Allogeneic Transplantation for aplastic anemia. In:  Thomas ED,  Blume KG,  Forman SJ editor. Hematopoietic Cell Transplantation. ed 2. Maiden, MA: Blackwell Science; 1999;p. 791–806
  77. Waid TH, Lucas BA, Amlot P, et al.  T1OB9.IA31 anti/T-cell monoclonal antibody. Preclinical studies and clinical treatment of solid organ allograft rejection. Am J Kidney Dis. 1989;14:61–70

☆ Supported by the Midwest Athletes Against Childhood Cancer (MACC) Fund.

PII: S0037-1963(00)90029-5

Seminars in Hematology
Volume 37, Issue 1 , Pages 43-55 , January 2000

Article Tools